LANGERHANS-CELL HISTIOCYTOSIS - EXCELLENT RESPONSE TO ETOPOSIDE

被引：9
|
作者：
MAYOU, SC
CHU, AC
MUNRO, DD
PLOWMAN, N
机构：
[1] ST BARTHOLOMEWS HOSP,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND
[2] ST BARTHOLOMEWS HOSP,DEPT DERMATOL,LONDON EC1A 7BE,ENGLAND
[3] HAMMERSMITH HOSP,DEPT DERMATOL,LONDON W12 ONN,ENGLAND
来源：
CLINICAL AND EXPERIMENTAL DERMATOLOGY | 1991年 / 16卷 / 04期
关键词：
D O I：
10.1111/j.1365-2230.1991.tb00379.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
We describe an adult with progressive LCH who received oral etoposide as primary treatment. The response is documented and the strategical implications of this drug in Langerhans-cell histiocytosis discussed. Langerhans-cell histiocytosis (LCH) is the term recognized since 1987 for the group of diseases previously designated histiocytosis X. 1 It is not now regarded as a malignant neoplastic process and there is some evidence to suggest that it is due to abnormal immunity, 2 but cytotoxic drugs and steroids are still the mainstay of systemic treatment. Etoposide (VP16) is a semisynthetic epipodophyllotoxin derivative effective in the treatment of malignancies of the monocyte-macrophage lineage and used in resistant or relapsed childhood LCH.3,4 There are no previous reports of its use as firstline monotherapy in adults with LCH.
引用
收藏
页码：292 / 294
页数：3
相关论文
共 50 条
  • [41] Langerhans-cell histiocytosis in an elderly patient: Case report and review of literature
    不详
    JOURNAL OF CUTANEOUS PATHOLOGY, 2006, 33 (01) : 72 - 72
  • [42] 2-CHLORODEOXYADENOSINE-INDUCED COMPLETE REMISSIONS IN LANGERHANS-CELL HISTIOCYTOSIS
    SAVEN, A
    FOON, KA
    PIRO, LD
    ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) : 430 - 432
  • [43] Multisystem Langerhans-cell histiocytosis with life-threatening pulmonary involvement-good response to cyclosporine A
    Zeller, B
    Storm-Mathisen, I
    Smevik, B
    Lie, SO
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 35 (04): : 438 - 442
  • [44] Diabetes insipidus in pediatric onset langerhans cell histiocytosis with excellent response to treatment
    Rai, Versha Rani
    Awais, Rimsha
    Rathore, Heeranand
    Ibrahim, Mohsina Noor
    Riaz, Maira
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 555 - 555
  • [45] Langerhans' cell histiocytosis - Response
    Vital, A
    JOURNAL OF NEUROSURGERY, 1998, 88 (04) : 790 - 790
  • [46] P.002 Vascular Bed Properties in Multisystemic Langerhans-Cell Histiocytosis
    K. Alexandraki
    P. Makras
    A. Protogerou
    A. Stathopoulou
    K. Dimitriou
    D. Papadogias
    E. Voidonikola
    G. Piaditis
    C. Papamichael
    G. Kaltsas
    Artery Research, 2006, 1 (Suppl 1) : S28 - S28
  • [47] SUCCESSFUL TREATMENT OF MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS (HISTIOCYTOSIS-X) WITH ETOPOSIDE
    YU, LC
    SHENOY, S
    WARD, K
    WARRIER, RP
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1994, 16 (03): : 275 - 277
  • [48] Erdheim–Chester disease of the breast associated with Langerhans-cell histiocytosis of the hard palate
    V. P. Andrade
    C. C. V. Nemer
    A. N. L. Prezotti
    W. S. L. Goulart
    Virchows Archiv, 2004, 445 : 405 - 409
  • [49] ETOPOSIDE IN THE TREATMENT OF 6 CHILDREN WITH LANGERHANS CELL HISTIOCYTOSIS (HISTIOCYTOSIS-X)
    VIANA, MB
    OLIVEIRA, BM
    SILVA, CM
    LEITE, VHR
    MEDICAL AND PEDIATRIC ONCOLOGY, 1991, 19 (04): : 289 - 294
  • [50] Langerhans-cell histiocytosis (LCH) in adults: Report of two cases and review.
    Stockschlaeder, M
    Juhl, D
    Sucker, C
    BLOOD, 2002, 100 (11) : 36B - 36B
12345